A Phase 3 interventional study of MK0954, /Duration of Treatment : 5 Years and Comparator : atenolol /Duration of Treatment : 5 Years in Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart), sponsored by Organon and Co. Completed. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-02-15.
Sponsored by Organon and Co · Phase 3, Interventional, and Prevention
Among 26 studies in Hypertension by Organon and Co — none open to participants now, none under way, none of them phase 3. Hypertension · Organon and Co.
Among the 26 studies in Hypertension by Organon and Co, this one is the 5th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 1995, is one of 16 in phase 3, and was the 6th registered.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's enrollment of 496 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →None of the 26 studies in Hypertension by Organon and Co is open now.
Of the 564 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →26 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 1995.
Median enrollment 261 across the 23 interventional studies, 669 across the 3 observational. Of the 26 that completed or were terminated, 15 (58%) have results posted.
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Hypertension by Organon and Co, from their registry updates:
Nothing recorded among them since 2026-09-25.
The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)
cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus
No study locations are listed for this record.
The record gives a start of Jun 1995, a primary completion of Sep 2001 and a completion of Nov 2001. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.